Table 2.

Clinical and demographic characteristics of the potential donors included in the two study phases

Characteristics		Phase 1	Phase 2	p value
		(N = 18)	(N=24)
Male gender		11 (61.1)	16 (64)	0.71
Age (years)		39.4±15	49.8±19.6	0.07
Cause of brain death
	Brain trauma	9 (50)	8 (32)	0.27
	Stroke	6 (33.3)	14 (60)	0.21
	Other	3 (16.6)	2 (8)	0.41
Temperature (ºC)
	t0	36.4±1.1	36.3±1.6	0.83
	t1	36.4±0.9	36.8±0.7	0.17
HR (bpm)
	t0	107±25	106±27	0.83
	t1	104±28	106±23	0.82
MAP (mmHg)
	t0	88±22	95±22	0.25
	t1	73±30	93±11	<0.02
Vasopressor (NA units#)
	t0	0.14±0.16	0.18±0.23	0.63
	t1	0.12±0.23	0.07±0.10*	0.36
Fluid infusion (mL)
	t0 (24 hours before)	4.972±5.096	4.759±4.224	0.88
	t1	2.897±3.604	5.247±4.073	0.07
Urine output (mL/kg/h)
	t0 (24 hours before)	2.21±2.17	2.35±2.14	0.83
	t1	0.95±1.03	2.5±1.73	<0.05
pH
	t0	7.26±0.16	7.26±0.15	0.93
	t1	7.24±0.12	7.36±0.12**	<0.02
Base deficit
	t0	-7.0±6.4	-4.9±4.4	0.21
	t1	-7.8±6.6	-3.5±3.9	<0.03
PaO2/FiO2
	t0	209±77	304±182	0.08
	t1	194±116	388±334	0.10
Glycemia (mg/dL)
	t0	153±49	157±35	0.65
	t1	151±39	215±71***	<0.008
Lactate (mmol/L) (t1)		1.4±0.5	1.9±0.9	0.24
Hematocrit (%) (ti)		30.5±7.6	30.1±5.8	0.84
Sodium (mEq/L) (ti)		147±8.7	149±7.2	0.46
Creatinine (t1)		1.8±2.3	0.8±0.6	<0.05

t0 - first clinical assessment; t1 - before recovery; HR - heart rate; MAP - mean arterial pressure; PaO₂/FiO₂ - partial pressure of oxygen/fraction of inspired oxygen.

^#Uniformed doses of vasopressor agents in noradrenaline units. Differences between t0 and t1 in Phase 2:

^*p=0.053;

^**p=0.015;

^***p=0.001. Results expressed as absolute number and percentage, mean ± standard deviation.